Significance statement:
We investigated the clinical impacts of COVID-19 infections on the rate
of disease relapses among chronic immune thrombocytopenia (ITP) patients
admitted to the Cleveland Clinic enterprise. Treatment guidelines for
COVID-19 associated ITP or diseases relapses are limited due to lack of
experience. We also reported different treatment used in patients who
relapsed and response rates to different treatment protocols, including
observation, which is important to guide treatment in this unique
patients population.